Financials data is unavailable for this security.
View more
Year on year RPG Life Sciences Limited grew revenues 13.50% from 5.13bn to 5.82bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 29.60% net income growth from 676.40m to 876.60m.
| Gross margin | 68.42% |
|---|---|
| Net profit margin | 15.39% |
| Operating margin | 19.48% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, cash reserves at RPG Life Sciences Limited fell by 51.00m. However, the company earned 943.60m from its operations for a Cash Flow Margin of 16.21%. In addition the company used 791.50m on investing activities and also paid 203.10m in financing cash flows.
| Cash flow per share | 66.80 |
|---|---|
| Price/Cash flow per share | 37.24 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 33.33% and 29.60%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
| Div yield(5 year avg) | 1.46% |
|---|---|
| Div growth rate (5 year) | 46.14% |
| Payout ratio (TTM) | 28.66% |
| EPS growth(5 years) | 51.98 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 29.05 |
More ▼
